Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
The European Respiratory Journal|June 18, 2021
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settingsPalwasha Y Khan, Molly F Franke, Catherine Hewison, et al.
Journal of Pediatric Psychology|June 14, 2024
Proof of concept of the Universal Baby video innovation for early child development in Lima, PeruAdrianne K Nelson, Christa J Griest, Llubitza M Munoz, et al.
The Journal of Infectious Diseases|April 9, 2020
Peripheral Blood Mucosal-Associated Invariant T Cells in Tuberculosis Patients and Healthy Mycobacterium tuberculosis-Exposed ControlsSara Suliman, Anele Gela, Simon C Mendelsohn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 14, 2022
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB CohortCatherine Hewison, Uzma Khan, Mathieu Bastard, et al.
Tropical Medicine & International Health : TM & IH|July 29, 2024
Prevalence of non-communicable diseases among household contacts of people with tuberculosis: A systematic review and individual participant data meta-analysisYohhei Hamada, Matteo Quartagno, Farihah Malik, et al.
The New England Journal of Medicine|January 29, 2025
Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible TuberculosisLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
Plos Medicine|September 12, 2019
Vitamin D status and risk of incident tuberculosis disease: A nested case-control study, systematic review, and individual-participant data meta-analysisOmowunmi Aibana, Chuan-Chin Huang, Said Aboud, et al.
The Lancet. Respiratory Medicine|July 19, 2025
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trialLorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, et al.
The Lancet. Child & Adolescent Health|March 16, 2023
Development of treatment-decision algorithms for children evaluated for pulmonary tuberculosis: an individual participant data meta-analysisKenneth S Gunasekera, Olivier Marcy, Johanna Muñoz, et al.
The Lancet. Child & Adolescent Health|January 24, 2025
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysisAnthony J Garcia-Prats, Maria Garcia-Cremades, Vivian Cox, et al.
Pageof 15